Document Type : Original Article
Authors
- . Taher Entezari‑Maleki 1
- . Mohammad Taraz 2
- . Mohammad Reza Javadi 2
- . Mir Hamed Hajimiri 2
- . Kaeh Eslami 3
- . Iman Karimzadeh 4
- . Maysam Esmaeili 2
- . Kheirollah Gholami 5
1 1 Drug Applied Research Center, Department of Clinical Pharmacy, Shahid Madani Heart Center, Tabriz University of Medical Sciences, Tabriz, Iran Department of Clinical Pharmacy, 13‑Aban Drug and Poison Information Center, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Clinical Pharmacy, 13‑Aban Drug and Poison Information Center, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Clinical Pharmacy, 13‑Aban Drug and Poison Information Center, Tehran University of Medical Sciences, Tehran, Iran Department of Clinical Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Department of Clinical Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
5 Department of Clinical Pharmacy, 13‑Aban Drug and Poison Information Center, Tehran University of Medical Sciences, Tehran, Iran Department of Clinical Pharmacy, Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Objective: To assess and describe the call services delivered by drug and poison information
call center (DPIC) of 13‑Aban pharmacy, which is closely operated by the Department of
Clinical Pharmacy, College of Pharmacy affiliated to Tehran University of Medical Sciences.
Methods: All calls services including counseled and follow‑up calls provided by 13‑Aban
DPIC to health care professionals and public were collected, documented, and evaluated
in a 2 years period from July 2010 to June 2012 using the designed software. Data analysis
was done by SPSS version 16.0.
Findings: Totally 110,310 calls services delivered during a 2 years period. Among
healthcare professionals, pharmacists, general physicians, and nurses requested more call
services respectively (P = 0.001). DPIC could detect 585 potential cases of adverse drug
reactions (ADRs) and 420 cases of major drug‑drug interactions (DDIs).
Conclusion: This study by analyzing and reporting the two-years activities of one of
the major DPICs in Iran, showed that DPICs can offer drug consultation for healthcare
professional and public as well as detect and prevent ADRs and DDIs, and therefore can
promote patients’ health regarding drug therapy.
Keywords
- Burkholder D. Some experiences in the establishment and
operation of a drug information center. Am J Hosp Pharm
1963;20:506‑13.
2. Beaird SL, Coley RM, Crea KA. Current status of drug
information centers. Am J Hosp Pharm 1992;49:103‑6.
3. Calder G, Davies JS, McNulty H, Smith JC. Drug information
network in the United Kingdom National Health Service. Am
J Hosp Pharm 1981;38:663‑6.
4. Maguire ME, D’Arcy PF. Drug information services in
four capital cities in the United Kingdom. ‘A tale of four
cities’ – London (North East Thames), Cardiff, Belfast,
Edinburgh. J Clin Pharm Ther 1988;13:207‑12.
5. The Council of Europe Expert Group on Safe Medication
Practices, Creation of a better medication safety culture in
Europe: Building up safe medication practices. Council of
Europe; 2007. p. 1‑275. Available from: http://www.coe.int/v
t/e/social_cohesion/socsp/Medication%20Safety%20Report.
pdf. [Last accessed on 2007 May 08]. - 6. Markind JE, Stachnik JM. European drug information centers.
J Hum Lact 1996;12:239‑42.
7. Hall V, Gomez C, Fernandez‑Llimos F. Situation of drug
information centers and services in Costa Rica. Pharm
Pract (Granada) 2006;4:1‑7.
8. Narhi U. Drug information for consumers and patients review
of the research. Publ Nat Agency Med 2006;1:1‑40.
9. Rosenberg JM, Koumis T, Nathan JP, Cicero LA, McGuire H.
Current status of pharmacist‑operated drug information
centers in the United States. Am J Health Syst Pharm
2004;61:2023‑32.
10. Rosenberg JM, Schilit S, Nathan JP, Zerilli T, McGuire H.
Update on the status of 89 drug information centers in the
United States. Am J Health Syst Pharm 2009;66:1718‑22.
11. Vassilev ZP, Chu AF, Ruck B, Adams EH, Marcus SM.
Evaluation of adverse drug reactions reported to a poison
control center between 2000 and 2007. Am J Health Syst Pharm
2009;66:481‑7.
12. Angaran DM. Telemedicine and telepharmacy: Current
status and future implications. Am J Health Syst Pharm
1999;56:1405‑26.
13. Melnyk PS, Shevchuk YM, Remillard AJ. Impact of the dial
access drug information service on patient outcome. Ann
Pharmacother 2000;34:585‑92.
14. Bouvy ML, van Berkel J, de Roos‑Huisman CM, Meijboom RH.
Patients’ drug‑information needs: A brief view on questions
asked by telephone and on the Internet. Pharm World Sci
2002;24:43‑5.
15. Hands D, Stephens M, Brown D. A systematic review of the
clinical and economic impact of drug information services on
patient outcome. Pharm World Sci 2002;24:132‑8.
16. Rosenberg JM, Fuentes RJ, Starr CH, Kirschenbaum HL,
McGuire H. Pharmacist‑operated drug information centers
in the United States. Am J Health Syst Pharm 1995;52:991‑6.
17. Müllerová H, Vlcek J. European drug information
centres – Survey of activities. Pharm World Sci 1998;20:131‑5.
18. Malone PM, Kier KL, Stanovich JE. Drug Information:
A Guide for Pharmacists. 3th ed. New York: The McGraw‑Hill
Companies; 2007.
19. Shadnia S, Soltaninejad K, Sohrabi F, Rezvani M, Barari B,
Abdollahi M. The performance of Loghman‑Hakim drug and
poison information center from 2006 to 2008. Iran J Pharm Res
2011;10:647‑52.
20. Timpe EM, Motl SE. Frequency and complexity of queries to
an academic drug information center, 1995‑2004. Am J Health
Syst Pharm 2005;62:2511‑4.
21. Saskatchewan Drug Information Service Annual Report
April 1, 2009 – March 31, 2010. College of Pharmacy and
Nutrition, University of Saskatchewan 110 Science Place,
Saskatoon SK S7N 5C9. Available from: http://medsask.usask.
ca/documents/annual-reports/2009-2010_SDIS_Annual_
Report.pdf. [Last accessed date 2014 June].
22. Pohjanoksa‑Mäntylä MK, Antila J, Eerikäinen S, Enäkoski M,
Hannuksela O, Pietilä K, et al. Utilization of a community
pharmacy‑operated national drug information call center in
Finland. Res Social Adm Pharm 2008;4:144‑52.
23. Churi S, Abraham L, Ramesh M, Narahari MG. Evaluation
of poison information services provided by a new poison
information center. Indian J Pharmacol 2013;45:496‑501.
24. de Sousa IC, de Lima David JP, Noblat Lde A. A drug
information center module to train pharmacy students in
evidence‑based practice. Am J Pharm Educ 2013;77:80.
25. Sarkar U, Handley MA, Gupta R, Tang A, Murphy E,
Seligman HK, et al. Use of an interactive, telephone‑based
self‑management support program to identify adverse events
among ambulatory diabetes patients. J Gen Intern Med
2008;23:459‑65.
26. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse
drug reactions in hospitalized patients: A meta‑analysis of
prospective studies. JAMA 1998;279:1200‑5.
27. Kavitha D. Adverse drug reaction (ADR) monitoring and
pharmacovigilance. J Pharm Res Health Care 2010;2:127‑34.
28. Ann. Guidance for Industry – Good Pharmacovigilance
Practices and Pharmacoepidemiologic Assessment. 2005. US
Food and Drug Administration. Available from: http://www.
fda.gov/downloads/Regulatory Information/Guidances/
UCM126834.pdf. [Last accessed on 2010 Mar 01].
29. Riedl MA, Casillas AM. Adverse drug reactions: Types and
treatment options. Am Fam Physician 2003;68:1781‑90.
30. Oberg KC. Adverse drug reactions. Am J Pharm Educ
1999;63:199‑204.
31. Moura CS, Acurcio FA, Belo NO. Drug‑drug interactions
associated with length of stay and cost of hospitalization.
J Pharm Pharm Sci 2009;12:266‑72.
32. Moura C, Prado N, Acurcio F. Potential drug‑drug
interactions associated with prolonged stays in the intensive
care unit: A retrospective cohort study. Clin Drug Investig
2011;31:309‑16.
33. Buajordet I, Ebbesen J, Erikssen J, Brørs O, Hilberg T. Fatal
adverse drug events: The paradox of drug treatment. J Intern
Med 2001;250:327‑41.
)